Displaying items by tag: cancer
Clinical trial evaluating a novel, non-invasive radiation treatment for ventricular tachycardia refractory to medication and catheter ablation The UAB Departments of Radiation Oncology and Cardiology are looking for patients with ventricular tachycardia (VT) not controlled by medications and catheter ablation. The trial will allow patients suffering from VT despite standard of care regimens to undergo non-invasive cardiac radioablation (CRA; a type of stereotactic body radiotherapy) to the area of the heart responsible for their symptoms. Stereotactic body radiotherapy is delivered with a device called the linear accelerator, which is primarily used to treat patients with cancer. UAB is one of the first centers in the U.S. to obtain a Food and Drug Administration (FDA) investigational device exemption for use of the linear accelerator in this capacity on a phase I/II trial. The study is being conducted in collaboration with the Washington University School of Medicine in St. Louis, a center which pioneered this promising technique in the U.S. For more information on the RAD 1901 trial, please contact Adelyn Gillon, clinical research coordinator, at 205.975.3019 or agillon@uabmc.edu" contenteditable="false">agillon@uabmc.edu.
Noha Sharafeldin, MBBCh, Ph.D., of the Institute for Cancer Outcomes and Survivorship, used UAB’s supercomputer to identify biomarkers linked with cognitive impairment in patients who received a blood or marrow transplant. She’s also testing a way to repair the damage.
We are conducting a study to examine the naturally occurring bacteria in the gut of women and how behaviors like diet and stress may affect the presence of bacteria in the gut. Participation includes completing questionnaires, basic body measurements, and providing samples of blood, stool, and saliva. Compensation is provided. For more information contact Sh’Nese Townsend at 205-934-1715 or stownsend@uabmc.edu
If you are experiencing extreme tiredness and fatigue even after your cancer treatment ends, you may be eligible to participate in a new mind/body research study. To qualify for this study, you must be a Stage II, Stage III or Stage IV cancer survivor who has completed all cancer treatment at least 6 months ago and within the last 10 years. Compensation for time and travel will be provided. For more information, please call 205-934-6326.
We are inviting you to participate in the D.I.A.L. physical activity program for 12 weeks at no cost to you. What is it? Receive 12-weeks of physical activity information over the phone. Who can join? Any healthy adult age 21 or older and you do not have to currently be physically active to participate. Why be involved? Contribute to cancer prevention research and receive compensation for your involvement. Call 205-934-0504 to see if you qualify for the program.
